Belite Bio (BLTE) vs Grifols S.A. (GRFS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Belite Bio (BLTE) has outperformed Grifols S.A. (GRFS) over the past year, gaining 5.7% versus a loss of 3.0%. Grifols S.A. is the larger company by market cap ($5.55 billion vs $5.17 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | GRFS |
|---|---|---|
| Share price | $127.38 | $8.15 |
| Market cap | $5.17B | $5.55B |
| 1-day change | -15.65% | -0.61% |
| YTD return | -20.37% | -12.83% |
| 1-year return | +5.66% | -2.98% |
| 5-year return | — | -25.30% |
| P/E ratio (TTM) | — | 9.82 |
| Forward P/E | — | 6.55 |
| EPS (TTM) | $-2.84 | $0.83 |
| Dividend yield | 0.00% | 1.30% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-77.61M | — |
| 52-week high | $200.00 | $9.77 |
| 52-week low | $115.41 | $6.96 |
| Distance from 52-week high | -36.31% | -16.58% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +82.92% | +27.24% |
| Average volume | 195.65K | 628.64K |
| Shares outstanding | 40.61M | 258.22M |
| Employees | 41 | 25,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees
BLTE vs GRFS FAQ
Which is bigger, Belite Bio or Grifols S.A.?
Grifols S.A. (GRFS) is larger, with a market capitalization of $5.55B compared with $5.17B for Belite Bio (BLTE).
Which stock has performed better over the past year, BLTE or GRFS?
BLTE returned +5.66% over the past 12 months, compared with -2.98% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Belite Bio or Grifols S.A.?
Grifols S.A. pays a dividend yielding 1.30%, while Belite Bio does not currently pay a regular dividend.
Are Belite Bio and Grifols S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.